Searchable abstracts of presentations at key conferences in endocrinology

ea0063p708 | Pituitary and Neuroendocrinology 2 | ECE2019

Hypophysitis secondary to anti-pd1/pd-l1 blockade: variations in presentation, four distinct cases

Lanzolla Giulia , Viola Nicola , Brancatella Alessandro , Latrofa Francesco , Marcocci Claudio , Vitti Paolo , Lupi Isabella

PD-1/PD-L1 pathway is a key regulator in T-cell activation and tolerance. Nivolumab, pembrolizumab (a PD-1 inhibitors) and atezolizumab (a PD-L1 inhibitor) are monoclonal antibodies approved for treatment of advanced cancers. Autoimmune thyroid diseases are the most common immune-related adverse effects (IrAEs) occurring after anti-PD-1 or anti-PD-L1 therapy, whereas autoimmune hypophysitis is described more frequently in patients treated with anti-CTLA-4. IrAEs can be isolate...

ea0063p765 | Thyroid 2 | ECE2019

Thyroid disfunction during treatment with Nivolumab: nuances in clinical presentation

Brancatella Alessandro , Viola Nicola , Lanzolla Giulia , Vitti Paolo , Marcocci Claudio , Latrofa Francesco , Lupi Isabella

Context: Monoclonal antibodies to Immune Check Point inhibitors (ICPis) are powerful anti-cancer drugs. They trigger the immune system against cancer cells, blocking inhibitory signals of T-Cells. However, ICPi therapy can also stimulate autoimmune reactions, inducing the so-called immune-related adverse events (irAEs). Endocrinopathies are common iRAEs and thyroid disfunction is the most common endocrinopathy during ICP therapy. We report three cases of thyroid disfunction du...

ea0037ep1219 | Clinical Cases–Pituitary/Adrenal | ECE2015

Autoimmune hypophysitis: from pituitary expansion to empty sella: description of four cases

Marconcini Giulia , Lupi Isabella , Manetti Luca , Cosottini Mirco , Urbani Claudio , Martino Enio , Marcocci Claudio , Bogazzi Fausto

Four patients with autoimmune hypophysitis were followed since the diagnosis of the disease. All presented with severe headache, decreased libido, astenia. Case 1 and 3 presented polyuria and polydipsia. At MRI pituitary was enlarged, with high gadolinum uptake and stalk enlargement.Case 1, male 41 years. MRI volume: AP 13 mm, CC 7 mm. Hormonal assessment: central hypothyroidism, hypoadrenalism, hypogonadism, normal GH and IGF1, hyperprolactinemia, centr...

ea0022p613 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Tumor infiltrating lymphocytes but not serum pituitary antibodies are associated with poor clinical outcome after surgery in patients with pituitary adenoma

Lupi Isabella , Manetti Luca , Caturegli Patrizio , Menicagli Michele , Bevilacqua Genersoso , Bogazzi Fausto , Martino Enio

Serum pituitary antibodies (Pit Abs) and tumor infiltrating lymphocytes (TILs) have been described in a small percentage of pituitary adenomas but their clinical significance remains unknown.Aim of the study was to assess Pit Abs and TILs prevalence in patients with pituitary adenomas and to determine their influence on the clinical outcome. In this prevalence case–control study were enrolled 291 pituitary adenoma cases, (110 non-secreting, 30 ACTH-...

ea0056p835 | Pituitary - Clinical | ECE2018

IgG4-related neuroinfundibulo-hypophysitis treated by rituximab and corticosteroids

Lupi Isabella , Urbani Claudio , Manetti Luca , Cosottini Mirco , Brancatella Alessandro , Cappellani Daniele , Bogazzi Fausto

IgG4-related hypophysitis, a type of IgG4-related disease, is a rare condition. It appears to be sensitive to glucocorticoids in most patients, but its recurrence is likely.Clinical case: A 17 year-old girl was referred for hypotonic polyuria and polydipsia of 1 month duration. Water deprivation test was suggestive of central diabetes insipidus. Basal and dynamic assessment of pituitary anterior function were unremarkable. Patient did suffer from autoimm...

ea0099p102 | Pituitary and Neuroendocrinology | ECE2024

Establishing BMI-Related thresholds for the 1 mg dexamethasone suppression test: a retrospective analysis

Urbani Claudio , Corleo Davide , Venturi Caterina , Marconcini Giulia , Bogazzi Fausto , Lupi Isabella , Santini Ferruccio , Manetti Luca

Background: Cushing Syndrome (CS) is associated with metabolic disturbances, including obesity. The 1 mg Dexamethasone Suppression Test (1mgDST) is widely used to assess cortisol regulation in suspected CS patients. However, its interpretation may require adjustments based on individual factors, such as body mass index (BMI), due to obesity’s influence on cortisol metabolism. The literature offers differing cutoff values for obese patients. This study aimed to establish B...

ea0081ep774 | Pituitary and Neuroendocrinology | ECE2022

Cushing’s syndrome due to adrenocorticotropic hormone-secreting metastatic neuroendocrine pancreatic tumor: diagnostic workup and management

Cosentino Giada , Manetti Luca , Marconcini Giulia , Boggi Ugo , Marconcini Riccardo , Lupi Isabella , Cappellani Daniele , Urbani Claudio , Bogazzi Fausto

We report the clinical history of a 21-years old young female who, in February 2021, presented abdominal pain and biliary vomiting that lasted for two months. An esophagus-gastroduodenoscopy revealed a duodenal ulcerative lesion and proton pump inhibitory therapy was started with clinical benefit. One month later, the patient presented a facial acneiform rush with hirsutism for which she was referred to our attention. An abdominal MRI documented a well-circumscribed hyper-vasc...

ea0056p828 | Pituitary - Clinical | ECE2018

Temozolomide is effective for rapid control of hypercortisolism in aggressive acth-secreting pituitary tumors

Cappellani Daniele , Michela Gabelloni , Cosottini Mirco , Urbani Claudio , Marconcini Giulia , Manetti Luca , Marcocci Claudio , Bogazzi Fausto , Lupi Isabella

Background: Temozolomide is an alkylating chemoterapic agent that ties a methyl to guanine, causing a base-pair mismatch and a DNA damage, resulting in cell death. Due to its lipophilic nature and its ability to cross the blood-brain barrier, this drug was originally used for malignant gliomas and later for aggressive pituitary tumors and carcinomas. Temozolomide is now recommended as first-line chemotherapy by the recently published ESE Clinical Practice Guidelines. Here we p...

ea0081p464 | Thyroid | ECE2022

Steroid treatment in the management of destructive thyrotoxicosis induced by PD1 blockade

Brancatella Alessandro , Pierotti Laura , Lupi Isabella , Montanelli Lucia , Viola Nicola , Sgro Daniele , Sardella Chiara , Antonangeli Lucia , Brogioni Sandra , Cremolini Chiara , Marcocci Claudio , Santini Ferruccio , Latrofa Francesco

Objective: Destructive thyroiditis is the most common endocrine immune related adverse event (iRAEs) in patients treated with anti-PD1/PD-L1 agents. Given its self-limited course, current guidelines recommend no treatment for this iRAE. Nevertheless in patients with enlarged thyroid volume and a poor performance status, thyrotoxicosis may be particularly severe and harmful. Aim of the study is to evaluate if steroid treatment might be useful in improving thyrotoxicosis in subj...

ea0041ep863 | Pituitary - Basic | ECE2016

Polychlorinated biphenyls affect apoptosis of pituitary cells through extrinsic and intrinsic pathways

Raggi Francesco , Russo Dania , Urbani Claudio , Cappellani Daniele , Manetti Luca , Sardella Chiara , Lupi Isabella , Scattina Ilaria , Tomisti Luca , Marcocci Claudio , Martino Enio , Bogazzi Fausto

Introduction: Polychlorinated biphenyls (PCBs) are environmental pollutants that modulate endocrine functions, induce tumorigenesis, and regulate apoptosis in several tissues; however, their effects on the apoptosis of pituitary cells is unknown.The aim of this study was to evaluate the PCBs influence on the apoptosis of normal pituitary cells and elucidate the molecular mechanisms involved.Methods: Primary cell cultures from mouse...